Julie Blatt
Overview
Explore the profile of Julie Blatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blatt J, Hildebrandt C, Nieman E, Adams M, McNamee L, Borst A
Pediatr Blood Cancer
. 2025 Feb;
:e31610.
PMID: 39976419
Background: Vascular anomalies (VA) are rare developmental disorders due to somatic variants in intracellular growth signaling pathways. Although genetic evaluation is considered the standard of care for optimizing management, the...
2.
Ikomi C, Blatt J, Ghofrani S, Zhang R, Ross J, Law J
J Pediatr Endocrinol Metab
. 2024 Aug;
37(9):789-795.
PMID: 39113198
Objectives: Lymphedema (LD) in Turner syndrome (TS) is a commonly reported comorbidity, though its associations with karyotype and other comorbidities are poorly understood. Characteristics of patients with TS and LD,...
3.
Gaghan L, Sluder I, Sampath A, Wood J, Brondon J, Blatt J, et al.
Pediatr Dermatol
. 2024 Jul;
41(6):1134-1140.
PMID: 38967954
Cutaneous pyogenic granulomas (PGs) are common, benign vascular tumors of uncertain pathogenesis; however, a growing body of literature suggests that the formation of PGs may be secondary to genetic alterations...
4.
Kalbfell R, Cohen-Cutler S, Grisham E, Bereitschaft C, Borst A, Green A, et al.
Pediatr Blood Cancer
. 2023 Nov;
71(1):e30758.
PMID: 37933207
Background And Objectives: Initially developed as immunosuppressive agents, mammalian target of rapamycin (mTOR) inhibitors are currently used widely in the management of vascular malformations and tumors. The incidence of infectious...
5.
McLean T, Borst A, Hammill A, Iacobas I, Atkinson A, Shah T, et al.
J Pediatr Hematol Oncol
. 2023 Sep;
45(8):452-460.
PMID: 37749794
Infantile hemangioma (IH) is the most common benign tumor of infancy. For children with IH who require treatment, propranolol and other beta blockers have been shown to be safe and...
6.
Blatt J, Brondon J, Nieman E, Phillips K, Pandya A
Pharmacol Ther
. 2023 Aug;
250:108520.
PMID: 37625520
Vascular anomalies (VA) are developmental anomalies of veins, arteries, lymphatics or capillaries thought to be caused by mutations in genes that drive angiogenesis. Treatments targeting these genes are limited. We...
7.
Cohen-Cutler S, Blatt J, Bayliff S, Iacobas I, Hammill A, Sisk B
J Pediatr
. 2023 Jun;
261:113579.
PMID: 37353145
Objective: To characterize the current distribution, composition, and practice patterns of multidisciplinary vascular anomalies (VAs) teams in the US. Study Design: This is a cross-sectional survey of children's hospitals in...
8.
Borst A, Hammill A, Crary S, McLean T, Felton T, Blatt J
JAMA Netw Open
. 2023 May;
6(5):e2314829.
PMID: 37219903
Importance: Vascular malformations (VMs) are rare disorders of vasculogenesis associated with substantial morbidity. Improved understanding of their genetic basis is increasingly guiding management, but logistical barriers to obtaining genetic testing...
9.
Aw W, Cho C, Wang H, Cooper A, Doherty E, Rocco D, et al.
Sci Adv
. 2023 Feb;
9(7):eade8939.
PMID: 36791204
Somatic activating mutations of are associated with development of vascular malformations (VMs). Here, we describe a microfluidic model of -driven VMs consisting of human umbilical vein endothelial cells expressing activating...
10.
Tallent B, Padilla R, McKay C, Foreman A, Fan Z, Blatt J
J Pediatr Hematol Oncol
. 2023 Jan;
45(5):278-280.
PMID: 36706268
Central giant cell granuloma of the jaw (CGCJ) can be locally aggressive and result in facial and dental deformity. A child with CGCJ was treated surgically and with denosumab with...